Evidence map›Paper›PMID 38175422›Full record

ArticleBreast cancer (Tokyo, Japan)2024

Pilot trial of an electronic patient-reported outcome monitoring system in patients with metastatic breast cancer undergoing chemotherapy.

Naruto Taira, Yuichiro Kikawa, Takayuki Iwamoto, Yuichiro Miyoshi, Kyoko Hara, Seiji Yoshitomi, Hajime Hikino, Hirotoshi Takahashi, Daisuke Takabatake, Shinichiro Kubo and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Recent advances in non-pharmacological interventions for symptom burden management in breast cancer patients treated with ovarian function suppression.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Naruto TairaDepartment of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki City, Okayama, 701-0192, Japan. ntaira@med.kawasaki-m.ac.jp.ORCID http://orcid.org/0000-0003-4266-1117
Yuichiro KikawaDepartment of Breast Surgery, Kansai Medical University Hospital, Osaka, Japan.
Takayuki IwamotoDepartment of Breast and Thyroid Surgery, Kawasaki Medical School, 577 Matsushima, Kurashiki City, Okayama, 701-0192, Japan.
Yuichiro MiyoshiDepartment of Breast and Endocrine Surgery, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Kyoko HaraDepartment of Breast and Endocrine Surgery, Japanese Red Cross Okayama Hospital, Okayama, Japan.
Seiji YoshitomiDepartment of Breast and Endocrine Surgery, Japanese Red Cross Okayama Hospital, Okayama, Japan.
Hajime HikinoDepartment of Breast Surgery, Japanese Red Cross Matsue Hospital, Matsue, Japan.
Hirotoshi TakahashiDepartment of Breast and Endocrine Surgery, National Hospital Organization Fukuyama Medical Centre, Fukuyama, Japan.
Daisuke TakabatakeDepartment of Breast Surgery, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Shinichiro KuboDepartment of Breast and Thyroid Surgery, Fukuyama City Hospital, Fukuyama, Japan.
Masahiko IkedaDepartment of Breast and Thyroid Surgery, Fukuyama City Hospital, Fukuyama, Japan.
Hiroyoshi DoiharaDepartment of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan.
Tadahiko ShienDepartment of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan.
Hiromi OkuyamaAdvanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.
Yuko TanabeDepartment of Clinical Oncology, Toranomon Hospital, Tokyo, Japan.
Fumikata HaraDepartment of Breast Medical Oncology, Japanese Foundation for Cancer Research Cancer Institute Hospital, Tokyo, Japan.
Kosho YamanouchiDepartment of Breast and Endocrine Surgery, Nagasaki Harbor Medical Center, Nagasaki, Japan.
Yasuhiro HagiwaraDepartment of Biostatistics, School of Public Health, The University of Tokyo, Tokyo, Japan.
Masataka SawakiDepartment of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundElectronic patient-reported outcomes monitoring (ePROM) is a useful communication tool for patients and healthcare providers in cancer chemotherapy. In this study, we examined the feasibility of our newly developed ePROM system, which we refer to as "Hibilog".

methodsAn ePROM app was developed by extracting 18 items from the Patient-Reported Outcome-Common Terminology Criteria for Adverse Events (PRO-CTCAE). Symptom monitoring was conducted every two weeks for patients with metastatic breast cancer undergoing chemotherapy. The primary outcome was the response rate to the ePROM system. The secondary outcomes were response time, item missing rate, and distribution of responses for each symptom.

resultsA total of 71 cases (mean age 52.6 years) were analyzed. Performance status was 0 in 76% of the cases and 1 or higher in 24%. First-line treatment was being administered in 30% of cases, second-line treatment in 17%, and third-line or higher treatment in 53%. The response rate to the ePROM system from registration to week 40 remained high at around 80%, indicating good compliance. The average response time was 5.5 min and the missing rate for each item was below 0.4%. Among 1,093 responses, the top 3 symptoms causing interference with daily life were Fatigue (63%), Numbness and tingling (48%), and General pain (46%).

conclusionOur developed ePROM system was able to capture symptoms accurately in patients with metastatic breast cancer undergoing chemotherapy while maintaining a high response compliance.

Indexed as

Breast NeoplasmsElectronicsFemaleHumansMiddle AgedPatient Reported Outcome MeasuresPilot ProjectsQuality of LifeElectronic patient-reported outcomesMetastatic breast cancerSymptoms

Identifiers

PMID38175422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.